MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-base...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Genomics Proteomics
Autors principals: KOVACOVA, JULIA, JURACEK, JAROSLAV, POPRACH, ALEXANDR, KOPECKY, JINDRICH, FIALA, ONDREJ, SVOBODA, MAREK, FABIAN, PAVEL, RADOVA, LENKA, BRABEC, PETR, BUCHLER, TOMAS, SLABY, ONDREJ
Format: Artigo
Idioma:Inglês
Publicat: International Institute of Anticancer Research 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727077/
https://ncbi.nlm.nih.gov/pubmed/31467229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/cgp.20140
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars